China's efforts to advance innovation and industrial upgrading are reshaping its healthcare sector, prompting multinational companies to deepen their local presence and tap into the country's growing medical research capabilities, a senior executive said.
"China is not only an important market in BD's global strategy, but also a source of innovation for the world," said Jeffrey Chen, worldwide senior vice-president and general manager of BD China, in an interview with China Daily during the ninth China International Import Expo in Shanghai.
The US-based medical technology company is cultivating and strengthening cooperation with Chinese hospitals, researchers and enterprises, drawing on the country's growing research capabilities and distinct clinical needs, Chen said.
After more than three decades in China, BD has expanded its operations from introducing overseas products and establishing manufacturing facilities to research, innovation and professional training.
The company is now placing greater emphasis on joint research with domestic hospitals and clinicians to translate their research findings and patents into commercial applications, Chen said.
The CIIE has also helped connect medical innovation with market demand. About 95 percent of the products BD exhibits at the annual event secure faster regulatory approval in China, he said.
Chen said BD would continue to deepen local partnerships to advance medical innovation and bring new technologies to patients.
